CDR 609
Alternative Names: CDR-609Latest Information Update: 31 Dec 2025
At a glance
- Originator CDR-Life
- Class Antibodies; Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Oct 2025 Pharmacodynamics data from preclinical trial in Solid tumours presented at the International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 26 Jun 2025 Preclinical trials in Solid tumours in Switzerland (Parenteral) (CDR-Life pipeline; July 2025)
- 26 Jun 2025 CDR-Life plans IND-enabling studies for Solid tumours in the second half of 2025 (Parenteral)